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Abstract: In preeclampsia, widespread maternal endothelial dysfunction is often secondary to
excessive generation of placental-derived anti-angiogenic factors, including soluble fms-like tyrosine
kinase-1 (sFlt-1) and soluble endoglin (sEng), along with proinflammatory cytokines such as tumour
necrosis factor-α (TNF-α) and activin A, understanding of which offers potential opportunities for
the development of novel therapies. The antimalarial hydroxychloroquine is an anti-inflammatory
drug improving endothelial homeostasis in lupus. It has not been explored as to whether it can
improve placental and endothelial function in preeclampsia. In this in vitro study, term placental
explants were used to assess the effects of hydroxychloroquine on placental production of sFlt-1,
sEng, TNF-α, activin A, and 8-isoprostane after exposure to hypoxic injury or oxidative stress.
Similarly, human umbilical vein endothelial cells (HUVECs) were used to assess the effects of
hydroxychloroquine on in vitro markers of endothelial dysfunction. Hydroxychloroquine had no
effect on the release of sFlt-1, sEng, TNF-α, activin A, or 8-isoprostane from placental explants exposed
to hypoxic injury or oxidative stress. However, hydroxychloroquine mitigated TNF-α-induced
HUVEC production of 8-isoprostane and Nicotinanamide adenine dinucleotide phosphate (NADPH)
oxidase expression. Hydroxychloroquine also mitigated TNF-α and preeclamptic serum-induced
HUVEC monolayer permeability and rescued the loss of zona occludens protein zona occludens 1
(ZO-1). Although hydroxychloroquine had no apparent effects on trophoblast function, it may be a
useful endothelial protectant in women presenting with preeclampsia.
Keywords: hydroxychloroquine; preeclampsia; sFlt-1; sEng; TNF-α; endothelial dysfunction
1. Introduction
Preeclampsia complicates 3%–5% of all pregnancies and remains one of the leading causes
of maternal and perinatal morbidity and mortality [1]. In particular, pregnancies complicated by
early onset preeclampsia (prior to 34 weeks gestation) are associated with a 20-fold increase in
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maternal death [2] and considerably increased rates of maternal and perinatal morbidities [3]. As such,
the management of early onset preeclampsia continues to pose significant challenges to obstetricians
attempting to balance maternal risks with fetal benefits of prolonging pregnancy.
Although not fully understood, the pathophysiology of preeclampsia is generally agreed to
originate with poor placentation [4]. Inadequate trophoblast invasion and failure of maternal
spiral arterial remodeling leads to impaired placental development, including exposure to chronic
progressive ischaemia–reperfusion injury characterized by evidence of excessive oxidative stress.
In turn, this induces excessive placental release of anti-angiogenic factors such as soluble fms-like
tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), coupled with inflammatory cytokines including
tumour necrosis factor-α (TNF-α) and activin A [5–8]. These various factors target the maternal
vasculature and contribute significantly to the widespread maternal vascular dysfunction, which is
often associated with oxidative injury [9–12]. Dysfunctional cells of the vasculature are characterized
by increased endothelial cell permeability, altered distribution of endothelial junctional proteins,
and reduced endothelium-dependent relaxation [13,14].
Antimalarials, such as hydroxychloroquine, were first formally used as a treatment for cutaneous
lupus in 1894. Following the observation in the 1940s that they had improved rheumatoid arthritis,
they became a popular therapy in rheumatic diseases [15]. However, research has only recently
unraveled some of the mechanisms of hydroxychloroquine’s therapeutic effect, as observed by
Wallace et al. 2012 [16]. Hydroxychloroquine is classified as C under the U.S. Food and Drug
Administration pregnancy category because it crosses the placenta but has not been reported to cause
any teratogenic effects to the fetus [17,18]. It has both anti-inflammatory and immunomodulatory
properties [19–21], and is widely used in autoimmune disorders such as systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA), and Sjogren’s syndrome. The exact mechanisms by which
hydroxychloroquine improves the activity of these disorders are still not fully understood. However,
in women with SLE, it has been shown to decrease circulating levels of pro-inflammatory cytokines
IL-6, IL-8, and TNF-α [22], as well as IL-17 and IL-22, which are cytokines produced by helper T
cells [23]. Recently, in a female mouse model of SLE, it was reported that hydroxychloroquine decreased
endothelial oxidative stress by reducing Nicotinanamide adenine dinucleotide phosphate (NADPH)
oxidase activity, which led to improved endothelial function, lower blood pressure, and a reduction in
proteinuria [24].
In preeclampsia, NADPH oxidase-dependent oxidative stress is one of the pathways underlying
the maternal endothelial dysfunction [12]. Accordingly, we hypothesize that hydroxychloroquine may
confer beneficial effects in women diagnosed with preeclampsia by reducing placental production of
potentially deleterious mediators, thus improving the overall maternal endothelial homeostasis.
2. Results
2.1. Effects of Hydroxychloroquine on Placental Secretion
Hypoxia significantly increased the secretion of sFlt-1 (Figure 1a, p = 0.02), sEng (Figure 1b, p =
0.02), and TNF-α (Figure 1c, p = 0.02) from explant cultures after 24 h incubation. In the presence of
X-XO (xanthine/xanthine oxidase system), explants cultured for 48 h significantly increased secretions
of 8-isoprostane (Figure 2a, p = 0.03) and activin A (Figure 2b, p = 0.01) compared to controls.
Co-incubation with 1 µg/mL hydroxychloroquine did not alter either the hypoxia-induced secretion of
sFlt-1 (Figure 1a), sEng (Figure 1b), or TNF-α (Figure 1c), or the X-XO-induced increase in 8-isoprostane
(Figure 2a) and activin A (Figure 2b).
2.2. Effect of Hydroxychloroquine on HUVEC Viability
Previously we have demonstrated that, compared to untreated controls, there was no effect of
hydroxychloroquine on human umbilical vein endothelial cell (HUVEC) viability across a dose
range of 0.1, 1, and 10 µg/mL over 120 h in culture [25]. However, treatment of cells with
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100 µg/mL hydroxychloroquine significantly reduced cell viability at 24 h (p < 0.001) [25]. Dosing of
hydroxychloroquine for all subsequent experiments were based on these results.
Figure 1. Release of (a) soluble fms-like tyrosine kinase-1 (sFlt-1), (b) soluble endoglin (sEng),
and (c) tumour necrosis factor-α (TNF-α) by placental explants of human term normal pregnancy
placentae after 24 h incubation at 5% oxygen concentration (normoxia) versus 1% oxygen (hypoxia).
The explants were incubated in the hypoxic environment in the absence or presence of 1 µg/mL
hydroxychloroquine. Data are mean ± standard error of the mean (SEM) from 10 independent
biological replicates. * denotes p < 0.05. NT: non treated, HCQ: hydroxychloroquine.
Figure 2. Release of (a) 8-isoprostane and (b) activin A by placental explants of human term normal
pregnancy placentae after 48 h incubation at 20% oxygen concentration with 5% CO2. The explants
were incubated in media containing xanthine (2.3 mM) + xanthine oxidase (15 mU/mL) in the absence
or presence of 1 µg/mL hydroxychloroquine. Data are mean ± SEM from 10 independent biological
replicates. * denotes p < 0.05. X/XO: xanthine/xanthine oxidase, HCQ: hydroxychloroquine.
2.3. Effects of Hydroxychloroquine on Endothelial Function In Vitro
HUVECs were treated in the absence or presence of (i) TNF-α (100 ng/mL), (ii) sera from
normal pregnancies (20%), or (iii) sera from preeclamptic women (20%) in the presence or absence of
hydroxychloroquine (1 µg/mL) to assess endothelial dysfunction (Figure 3). Compared to controls,
incubation of HUVECs with TNF-α (Figure 3a,c) or sera from preeclamptic women (Figure 3b,d)
significantly increased both NADPH oxidase 2 (NOX2) mRNA expression (p < 0.001 and p = 0.01,
respectively) and 8-isoprostane secretion (p = 0.02 and p = 0.04, respectively). Co-treatment of HUVECs
with TNF-α and hydroxychloroquine significantly reduced NOX2 mRNA expression (Figure 3a,
p = 0.03) and secretion of 8-isoprostane (Figure 3c, p = 0.04). Co-treatment of HUVECs with serum
from preeclamptic women and hydroxychloroquine did not significantly alter the expression of NOX2
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mRNA or 8-isoprostane. However, 100 µM apocynin, a NOX inhibitor, significantly reduced the NOX2
mRNA expression and 8-isoprostane release induced by serum from preeclamptic women (Figure 3b,d,
respectively, p < 0.01 for both).
Figure 3. NADPH oxidase 2 (NOX2) RNA expression of human umbilical vein endothelial cells
(HUVECs) treated with 100 ng/mL TNF-α (a) and 20% preeclampsia (PE) sera (b). Release of
8-isoprostane by HUVECs treated with 100 ng/mL recombinant TNF-α (c) and 20% preeclampsia
sera (d). Data are mean ± SEM from eight independent biological replicates. * denotes p < 0.05;
****p<0.001.
Compared to controls, incubation of HUVECs with TNF-α (Figure 4a) or 20% sera from
preeclamptic women (Figure 4b) increased immunoreactivity for NOX2 protein. Once again,
co-treatment of HUVECs with TNF-α and either apocynin or hydroxychloroquine reduced
immunoreactive NOX2 protein expression (Figure 4a). Similarly, co-treatment of HUVECs with
sera from preeclamptic women and either apocynin or hydroxychloroquine also showed reduced
immunoreactive NOX2 protein expression (Figure 4b).
Figure 4. Western blot representative for NOX2 protein expression of HUVECs untreated (cont) or
treated with 100 ng/mL TNF-α (a) or 20% preeclampsia (PE) sera (b) with or without apocynin (apo,
100 µM) or hydroxychloroquine (HCQ, 1 µg/mL). β-actin was used as a loading control.
2.4. Effect of Hydroxychloroquine on Vascular Permeability
Both TNF-α (Figure 5a) and sera from preeclamptic women (Figure 5b) significantly increased
HUVEC monolayer permeability compared to controls (p = 0.02 and p = 0.005, respectively). These effects
were mitigated by co-treatment with hydroxychloroquine (p = 0.04 and p = 0.007, respectively).
Hydroxychloroquine prevented the significant loss of zonula occludens 1 (ZO-1) induced by both
TNF-α (Figure 5c, p = 0.003) and sera from preeclamptic women (Figure 5d, p = 0.02).
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Figure 5. HUVECs’ permeability when treated with 100 ng/mL recombinant TNF-α (a) and 20%
preeclampsia sera (b) (n = 9). Mean zonula occludens 1 (ZO-1) fluorescence when treated with
100 ng/mL recombinant TNF-α (c) and 20% preeclampsia sera (d) (n = 6). Data are means ± SEM from
nine and six independent biological replicates, respectively. * denotes p < 0.05, and ** denotes p < 0.005.
2.5. Effect of Hydroxychloroquine on Zonula Occludens 1 (ZO-1) Immunohistochemistry
Figure 6 contains representative images of ZO-1 immunostaining. There was normal ZO-1
immunostaining in untreated or HUVECs treated with sera from normal pregnancies (Figure 6A,D),
with the loss of immunostaining in cells treated with either TNF-α (Figure 6B) or preeclampsia sera
(Figure 6E). Hydroxychloroquine rescued the loss of ZO-1 induced by both TNF-α (Figure 6C) and
preeclampsia sera (Figure 6F).
Figure 6. Immunofluorescent staining of ZO-1 on HUVECs treated with 100 ng/mL recombinant TNF-α
or 20% preeclampsia sera for 16–22 h. Representative images from one of six experiments are shown.
(A) Control untreated HUVECs, (B) TNF-α 100 ng/mL, (C) TNF-α 100 ng/mL with hydroxychloroquine
1 µg/mL, (D) control HUVECs treated with 20% normal pregnancy sera, (E) 20% preeclampsia sera,
and (F) preeclampsia sera with hydroxychloroquine 1 µg/mL. Arrows show the ZO-1 staining on the
endothelial cell border.
3. Discussion
We undertook the study to explore the potential of hydroxychloroquine as a novel targeted therapy
addressing key pathophysiological pathways in preeclampsia. We demonstrated that this antimalarial
drug affords no apparent protection against hypoxia or oxidative stress in placental explants but that
it does have endothelial protective properties. These observations suggest that hydroxychloroquine
is a potential therapy for women with established preeclampsia but is unlikely to be useful as a
preventative treatment.
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We hypothesized that hydroxychloroquine would protect placental tissue from hypoxia-induced
injury ex vivo. Specifically, we sought to show that hydroxychloroquine could mitigate the effects of
hypoxia and hyperoxia on the placental release of the anti-angiogenic factors sFlt-1 and sEng, as well
as on the release of the pro-inflammatory cytokines, TNF-α, and activin A. However, we found this not
to be the case. Hydroxychloroquine had no effect on modulating hypoxia-induced placental injury.
These findings support those of others who tested hydroxychloroquine in a trophoblast-derived cell
line exposed to antiphospholipid antibodies as a model of antiphospholipid syndrome [26]. They found
that although hydroxychloroquine was able to mitigate trophoblast secretion of IL-6, it had no effect on
sEng release [26]. Collectively, this suggests that in an established diagnosis of preeclampsia, the use of
hydroxychloroquine may not confer any beneficial effects.
The maternal symptoms of preeclampsia are largely due to widespread maternal endothelial
dysfunction [27,28]. Lupus shares this feature as the key mechanism underlying hypertension,
renal dysfunction, and other organ injury [29]. Indeed, the endothelial dysfunction in both
preeclampsia and lupus have also been shown to be due, at least in part, to excessive oxidative stress
secondary to NOX activation [12,30,31]. Recently, in murine models of lupus, hydroxychloroquine
was shown to reverse endothelial dysfunction via the downregulation of NOX, and subsequently,
oxidative stress [24,32]. Here, we showed that hydroxychloroquine may have similar effects in
an in vitro model of preeclampsia-like endothelial dysfunction. Specifically, hydroxychloroquine
was able to prevent the TNF-α induction of NOX2 and subsequent oxidative stress in HUVECs
but, importantly, was not able to block similar effects induced by sera from preeclamptic women.
Interestingly, apocynin, a NOX inhibitor, was able to prevent the effects of both TNF-α and sera from
preeclamptic women on NOX2. This confirms the pro-oxidative effects of the sera of preeclamptic
women are mediated via NOX2 [12]. Müller-Calleja et al. demonstrated the inhibition of reactive
oxygen species (ROS) generated by endosomal NOX in human monocytic cells [33]. However,
the concentration used was much higher (10 µM) but still within therapeutic range as compared
to ours (3.6 µM). It is apparent that the concentration of hydroxychloroquine differs in various cell
types in in vitro experiments. Although several isoforms of NOX family members including NOX1,
NOX2 (also called gp91phox), NOX3, NOX 4, and NOX 5 have been reported to date, in endothelial
cells, NOX1, NOX2, and NOX4 isoforms are reported to be involved in the inflammatory response and
cytokine expression, triggered by angiotensin II treatment, through different mitogen activated protein
kinases (MAPK) pathway activation (phosphorylated form of p38 MAPK, extracellular signal regulated
kinases, ERK-1/2 and stress-activated protein kinases and c-jun N-terminal kinase, SAPK/JNK) [34].
We have shown before that follistatin, an activin binding protein, can block the endothelial
effects of sera from preeclamptic women [12,35]. Compared to women with a normal pregnancy,
maternal circulating levels of activin are increased approximately 10-fold in women with
preeclampsia [36]. We have not yet explored whether hydroxychloroquine can block activin-mediated
effects. However, the current study suggests that sera from preeclamptic women contains factors
capable of inducing NOX, which cannot be mitigated by hydroxychloroquine.
Intriguingly, hydroxychloroquine was able to mitigate the effects of both TNF-α and sera from
preeclamptic women on the loss of endothelial ZO-1 and integrity. Endothelial ZO-1 is a protein
present in endothelial cell–cell junction known to regulate cellular permeability [37]. Any changes
in ZO-1 protein, such as induced by a response to inflammatory cytokines, will alter the endothelial
cell permeability. The loss of ZO-1 induced by TNF-α is known to be mediated via the activation of
NOX [38,39]. Hydroxychloroquine was able to prevent the loss of ZO-1 and the subsequently increased
endothelial permeability induced by both TNF-α and sera from preeclamptic women, suggesting these
effects may be mediated through a TNF-α-dependent upregulation of NOX. Further evaluation is
required to verify this theory, perhaps using TNF-α receptor antagonists co-incubated with the sera of
preeclamptic women.
Circulating levels of TNF-α increase in normal pregnant women and are further raised in
preeclamptic women [40–42]. These levels are much lower than the concentrations tested in the present
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study (15 pg/mL vs. 100 ng/mL, respectively). Although in the in vitro model of acute exposure of cells
to single high dose may not be a good representation of the in vivo situation, previous studies have
reported that 100 ng/mL of TNF-α in cultured HUVEC enhanced endothelial cell activation, similar to
that observed in preeclampsia [43].
The effect of hydroxychloroquine on other pathogenic pathways of preeclampsia have not been
explored in this study. For example, it is now thought that a key mechanism of action of antimalarial
drugs is the antagonism of toll-like receptor (TLR) signaling and subsequent downstream activation of
pro-inflammatory cytokines [16,44]. In preeclampsia, placental expression of TLR3, TLR7, and TLR8 are
upregulated [45,46]. The treatment of pregnant rodents with TLR agonists induces a preeclampsia-like
phenotype, providing further evidence of other mechanistic pathways that hydroxychloroquine
treatment could also target.
In addition to the effects of antimalarial agents on TLRs, these drugs have other benefits, such as
inhibition of phospholipase A2 (PLA2) enzyme. PLA2 has been implicated in the pathogenesis
of preeclampsia and is found to be elevated in both decidual tissue and the sera of preeclamptic
women [47,48]. Similarly, in patients with active SLE, there is a 4.6-fold increase in the mean activity
of PLA2 [49]. Lipid peroxidation occurs because of oxidative stress induced by the elevated levels
of reactive oxygen species. This leads to membrane phospholipid degradation and hence release of
arachidonic acid [50]. Zabul et al. have described the potential role of arachidonic acid hydroperoxide
underlying the molecular mechanism of oxidative stress in preeclampsia [51]. Arachidonic acid
stimulates release of superoxide from neutrophils and macrophages [52]. Antimalarial drugs have
been shown to inhibit PLA2 activity and therefore reduce the generation of superoxide, which will be
beneficial for improving endothelial dysfunction in preeclamptic patients [50,53].
4. Materials and Methods
4.1. Blood and Tissue Collection
Preeclampsia is defined as elevation of blood pressure of 140/90 mmHg or more, and proteinuria
of more than 0.3 g in a 24 h urine collection or random urine dipstick test of more than 2+ according
to the Society of Obstetric Medicine of Australia and New Zealand guidelines [54]. All blood and
placental tissues were collected from pregnant women, as detailed below. Written and informed
consent was obtained from all individual participants included in the study with the approval of
the Monash Health Human Research Ethics Committee (HREC no. 13357B, dated 6 August 2015).
Venous blood was collected from women with a singleton healthy pregnancy and from women with
established preeclampsia at 24 to 34 weeks of gestation. Women who had received intravenous
magnesium sulphate, or had pre-existing or secondary hypertension, diabetes, or a multiple pregnancy,
were excluded. None of the women with preeclampsia were in labor at the time of blood sampling.
The control (healthy) women were matched for gestation (≤34 weeks). Sera were separated and pooled
into two groups: healthy term pregnancy serum and preeclampsia serum. For all in vitro experiments,
20% pooled sera from preeclampsia pregnancies were used for treatment of endothelial cells and were
compared with that of the normotensive sera treated cells. There were significant differences in the
systolic and diastolic blood pressure and proteinuria between normotensive and preeclamptic patients
(p = 0.007), as previously presented [25].
4.2. Placental Explant Cultures Ex Vivo
Placental villous explants (n = 10) were collected from term uncomplicated pregnancies at elective
caesarean section within 20 min of delivery of the placenta. Briefly, placental villous tissue was excised
by removing maternal decidua. Villous explants (approximately 50–70 mg wet weight) were then
thoroughly washed with cold Hank’s balanced salt solution (HBSS, 1:10, Life Technologies/Thermo
Fisher Scientific, Waltham, MA, USA) and placed in 24-well plates in M199 supplemented with
1% antibiotics/antimycotics (penicillin G, streptomycin sulphate, and amphotericin B) and 1% of
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L-glutamine (all from Life Technologies/Thermo Fisher Scientific, Waltham, MA, USA). Incubation
details are provided below.
4.3. Placental Hypoxia
Placental hypoxia was modeled by incubating placental explants in 1% oxygen with 5% CO2 at
37◦C in the presence or absence of 1µg/mL hydroxychloroquine (Sigma-Aldrich, St. Louis, Missouri,
USA). Controls were incubated in 5% oxygen. The conditioned media were collected after 24 h and
stored at -80◦C for sFlt-1, sEng, TNF-α, and activin A assay.
4.4. Placental Oxidative Stress
The explants were treated with 2.3 mM xanthine (X) and 0.015 U/mL xanthine oxidase (XO)
(Sigma-Aldrich) to induce oxidative stress [8,55]. Explants were incubated in X/XO in the presence or
absence of 1 µg/mL hydroxychloroquine for 48 h at 37 ◦C in 20% oxygen, 5% CO2. Untreated cultures
served as controls. Conditioned media were collected and stored at -80 ◦C in the presence of 0.005%
butylated hydroxytoluene (BHT) (Sigma-Aldrich, St. Louis, Missouri, USA) to prevent autoxidation
for activin A and 8-isoprostane assay measurements. Elevated levels of 8-isoprostane are a marker for
lipid peroxidation caused by oxidative stress [56] and, in addition, high levels of activin A have been
implicated in the pathway of placental oxidative stress [12].
4.5. Measurement of sFlt-1, sEng, TNF-α, and Activin A with ELISA
Levels of sFlt-1, sEng, TNF-α, and activin A were measured in placental explant (n = 10)
conditioned media using Quantikine immunoassay ELISAs (R&D systems, Minneapolis, Minnesota,
USA) according to the manufacturer’s protocol. All samples were assayed in duplicate. Briefly, for the
measurement of sFlt-1, sEng, TNF-α, and activin A, the conditioned media was diluted (1:40, 1:10, 1:5,
and 1:30, respectively) with assay diluent. Results were normalized per milligram weight of tissue.
4.6. Human Umbilical vein Endothelial Cell (HUVEC) Isolation
Umbilical cords were also obtained from healthy women with term singleton pregnancies
(n = 8) undergoing elective caesarean. HUVECs were isolated and cultured, as previously described,
with minor modifications [8,57]. Briefly, the umbilical cord was severed from the placenta within
an hour of collection. All areas with clamp marks were removed and the umbilical vein was
cannulated and tied with thread. After removal of blood, the umbilical veins were infused with type II
collagenase (0.5 mg/mL, Sigma-Aldrich) and incubated for 10 min at 37◦C to isolate the endothelial
cells. They were maintained in M199 complete media containing 20% heat-inactivated fetal calf
serum, 1% antibiotics/antimycotics (penicillin G, streptomycin sulphate, and amphotericin B), and 1%
l-glutamine with endothelial and fibroblast growth factor (10 ng/mL each). Only cells at passage 2 to 4
were used for experiments.
4.7. HUVEC Viability Assay
We first determined the effect of different concentrations of hydroxychloroquine on HUVEC
viability. Cells were plated at 2 × 104 cells per well in 96-well plates (n = 8, Corning) and grown
to confluence in 100 µL culture media with hydroxychloroquine added at different concentrations
(0.1, 1, 10, 100 µg/mL) and further incubated for 24 h. Viability was assessed by adding 20 µL MTS
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent (Promega, Madison, WI, USA)
to each well. After 1 h at 37 ◦C, the absorbance at 490 nm was read using a plate reader (SpectraMax i3,
Molecular Devices, San Jose, CA 95134 USA).
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4.8. Oxidative Stress as Assessed by 8-Isoprostane
Cells were grown to confluence in 96-well plates (2 × 104 cells per well) for 24 h in M199 complete
media. Cells were treated with media (control), 100 ng/mL TNF-α (Life Technologies /Thermo Fisher
Scientific, Waltham, MA, USA), 20% normal pregnancy sera, or 20% preeclampsia sera, in the presence
or absence of hydroxychloroquine (0, 0.1, 1, and 10 µg/mL) for a further 24 h. Conditioned media were
then stored at -80◦C in the presence of 0.005% butylated hydroxytoluene (BHT) as described above.
Total 8-isoprostane was measured using a commercial enzyme immunoassay (Cayman Chemical,
Ann Arbor, MI, USA) according to the manufacturer’s instructions. Samples were assayed in duplicate
after diluting 1:5 with assay diluent. On the basis of the results from this experiment, in all subsequent
experiments 1 µg/mL hydroxychloroquine was used. The cells were treated with either 100 ng/mL of
recombinant TNF-α or 20% preeclampsia sera in combination with either 1 µg/mL hydroxychloroquine
or 100 µM apocynin (NADPH oxidase inhibitor) (Sigma-Aldrich) for 24 h.
4.9. Measurement of NADPH Oxidase (NOX2) mRNA Expression
Cells were grown to confluence in 6-well plates (1 × 105 cells per well) for 48–72 h in M199
complete media. Cells were treated with 100 ng/mL recombinant TNF-α or 20% preeclampsia serum
combined with either 100 µM apocynin or 1 µg/mL hydroxychloroquine for 6 and 12 h, respectively.
The treatment groups were compared with untreated HUVECs or cells treated with 20% sera from
normotensive pregnant women. Total cellular RNA was isolated with Ambion (Life Technologies
/Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocols. The cDNA
was prepared with 1 µg of cellular mRNA and reverse-transcribed using SuperScript III first strand
synthesis system (Life Technologies). Quantitative PCR was performed on Rotorgene (Qiagen, Hilden,
Germany) in a reaction mixture (20 µL) containing Sensimix SYBR Green PCR master mix (Bioline
Meridian Biosciences, Heidelberg, Germany). The reactions were performed with the following
conditions: 95 ◦C for 10 min then 40 cycles of 95◦C for 20 s, 60 ◦C for 30 s, and 72 ◦C for 30 s. NOX2 was
amplified using primers 5′-TGG CAC CCT TTT ACA CTG-3′ and 5′-CCA CTA ACA TCA CCA CCT
CA-3′. The housekeeping gene 18S was amplified using primers 5′-GTC TGT GAT GCC CTT AGA
TGT C-3′ and 5′-AAG CTT ATG ACC CGC ACT TAC-3′. Relative gene expression was determined
using the delta delta – cycle threshold (CT) method.
4.10. Measurement of NOX2 Protein Expression
HUVECs were grown to confluence and treated with either 100 ng/mL recombinant TNF-α or 20%
preeclampsia serum combined with 100 µM apocynin or 1 µg/mL hydroxychloroquine for 6 and 12 h,
respectively. HUVECs were assessed for total NOX2 protein. Protein extracts of nucleic and cytoplasmic
fractions were obtained using the nuclear and cytoplasmic reagents (Life Technologies /Thermo Fisher
Scientific, Waltham, MA, USA) according to manufacturer’s instructions. Protein quantification was
performed using the Pierce Bicinchoninic acid (BCA) kit (Life Technologies /Thermo Fisher Scientific,
Waltham, MA, USA)). For Western blots, 40µg protein was loaded for each sample. Membranes were
then blocked with 5% (w/v) skim milk in phosphate-buffered saline with 0.1% (v/v) Tween-20 for 1 h
prior to probing with antibodies. Membranes were stripped in a mild stripping buffer (1.5% w/v glycine,
0.1% w/v sodium dodecyl sulfate, 1% v/v Tween-20 in distilled water) for 5 min between antibodies.
The primary antibodies and concentrations used were Nox2 at 0.025 ng/mL (anti-NOX2/gp91phox
antibody (ab80508, Abcam, Cambridge, United Kingdom) and the control β-actin at 0.01 ng/mL
(IMG-5142A, Imgenex). Antibodies were diluted in blocking buffer and incubated overnight at 4 ◦C.
Chemilumiscence detection was performed using Clarity Western Electrochemiluminescence (ECL)
blotting Substrates (Bio-Rad, Hercules, CA, USA).
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4.11. Endothelial Permeability Assay
An endothelial permeability assay was performed as previously described with minor
modifications [58]. Briefly, culture inserts (0.4 µm pore size, 6.5 mm diameter; Corning) were
coated with 0.2% gelatin (Sigma-Aldrich) for 30 min at room temperature. HUVECs (50,000 cells
per well) were plated on the inserts and cultured to form a tight monolayer with 100 µL M199
complete media in the upper chamber and 600 µL in the lower chamber at 37 ◦C, 5% CO2 for 72
h. Inserts were then transferred to a fresh plate and cell monolayers were treated in fresh media
containing 100 ng/mL recombinant TNF-α alone or with 1 µg/mL hydroxychloroquine for 16–22 h.
Treatment groups were compared with untreated HUVECs. The conditioned media were collected and
100 µL fresh media containing fluorescein isothiocyanate (FITC)-conjugated dextran (MW 40000, final
concentration 1 mg/mL, Sigma-Aldrich) was added to the upper chamber. The plate was incubated
while protected from light for 60 min. The media from the lower chamber were diluted (1:20) in HBSS
for measurement of fluorescence at 485/535 nm using a plate reader (SpectraMax i3, Molecular Devices).
Results (fluorescence units) were expressed as percent changes relative to control.
Assessment of cell permeability when treated with 20% sera from healthy or preeclamptic women
was performed using in vitro permeability assay kit from Millipore (Merck Millipore) in the absence
or presence of 1 µg/mL hydroxychloroquine for 16–22 h. The treatment groups were compared with
HUVECs treated with serum from women who had normal pregnancies (NP). Briefly, the transwells,
which were coated with collagen, were rehydrated with 250 µL endothelial growth media (EGM,
Lonza) and left at room temperature for 15 min. Subsequently, 200 µL of the media was removed and
replaced with an equal volume of cell stock (1 x 105). Then, 500 µL of media was added to the receiver
plate and incubated for 72 h to form a tight monolayer. Following this, fresh media was replaced in
the receiver plate. The cells were treated accordingly and further incubated for 16–22 h. Media in
the upper chamber was replaced with fresh media (150 µL) containing fluorescein isothiocyanate
(FITC)-conjugated dextran, and the plate was incubated for 30 min and protected from light. The media
from the lower chamber was diluted (1:20) with HBSS for measurement of fluorescence at 485/535 nm
using a plate reader (SpectraMax i3, Molecular Devices). Results (fluorescence units) were expressed
as percent changes relative to control.
4.12. Zonula Occludens (ZO-1) Immunohistochemistry for the Assessment of Endothelial Integrity
HUVECs were grown on 14 mm glass coverslips (4 × 104 cells/well) placed in 24 well plates.
Cells were treated with 100 ng/mL recombinant TNF-α or 20% sera from preeclamptic women
in the presence or absence of 1 µg/mL hydroxychloroquine for 16–22 h prior to fixing with 4%
paraformaldehyde (Sigma-Aldrich) for 30 min at room temperature. The treatment groups were
compared with untreated HUVECs or cells treated with 20% normal pregnancy sera. Cells were blocked
with 0.5% bovine serum albumin (BSA, Sigma-Aldrich) for 30 min, incubated first with rabbit anti-ZO-1
(1:50, Zymed) overnight at 4◦C, then with donkey anti-rabbit Alexa Fluor 568 (1:100, Invitrogen)
for 1 h in the dark. Cell nuclei were stained with 2 µm 4′,6-diamidino-2-phenyindole dilactate
(DAPI, Sigma Aldrich) for 10 min and mounted with fluorescent mounting media (DakoCytomation).
Staining was examined with an Olympus BX60 fluorescent microscope and images were taken using
an Olympus DP70 camera and Olympus CellSens software (Olympus). The primary antibody was
replaced with an isotype-matched control antibody in the negative controls. The mean intensity of the
staining was assessed using ImageJ software (version 2.0.0-rc-43/1.50i, http://imagej.net/Fiji/Downloads,
Bethesda, MD).
5. Conclusions
Hydroxychloroquine has a significant protective impact on endothelial function acting via the
suppression of NOX-induced oxidative stress; it is unable to mitigate all of the effects of preeclamptic
sera-induced injury in vitro or to mitigate ex vivo placental injury. Further evaluation is warranted
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to determine other molecular pathways by which hydroxychloroquine may prevent endothelial
dysfunction in preeclampsia. The results of this study strongly suggest that hydroxychloroquine seems
likely to be clinically effective as adjuvant therapy in women diagnosed with preeclampsia.
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